Literature DB >> 8652805

Kaposi's sarcoma-associated herpesvirus (KSHV or HHV8) in primary effusion lymphoma: ultrastructural demonstration of herpesvirus in lymphoma cells.

W Said1, K Chien, S Takeuchi, T Tasaka, H Asou, S K Cho, S de Vos, E Cesarman, D M Knowles, H P Koeffler.   

Abstract

Recent molecular evidence suggests an association with a new herpesvirus, Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8), and primary effusion lymphomas (PELs). PELs have a characteristic morphology, phenotype, and clinical presentation, with malignant effusions in the absence of a contiguous solid tumor mass. We have established a cell line (KS-1) from a KSHV-positive human immunodeficiency virus (HIV)-negative patient with pleural cavity-based lymphoma that was passaged into triple-immunodeficient BNX mice. In contrast to cell lines from body cavity-based lymphomas derived from HIV-positive individuals that contain both KSHV and Epstein Barr viral genome, these cells contain only KSHV, allowing for uncontaminated virologic studies. Ultrastructural examination identified malignant cells with features of late differentiating B cells (immunoblasts). Cells with viral cytopathic effect contained typical 110-nm intranuclear herpesvirus nucleocapsids and complete cytoplasmic virions, confirming the association of PEL with KSHV.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8652805

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

1.  Lymphoid disorders associated with HHV-8/KSHV infection: facts and contentions.

Authors:  G Gaidano; E Castaños-Velez; P Biberfeld
Journal:  Med Oncol       Date:  1999-04       Impact factor: 3.064

2.  Identification and analysis of the K5 gene of Kaposi's sarcoma-associated herpesvirus.

Authors:  M Haque; J Chen; K Ueda; Y Mori; K Nakano; Y Hirata; S Kanamori; Y Uchiyama; R Inagi; T Okuno; K Yamanishi
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

3.  Anti-CD20 monoclonal antibody treatment of human herpesvirus 8-associated, body cavity-based lymphoma with an unusual phenotype in a human immunodeficiency virus-negative patient.

Authors:  C L Pérez; S Rudoy
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

Review 4.  Human herpesvirus 6.

Authors:  D K Braun; G Dominguez; P E Pellett
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

5.  Carboxyl-terminal amino acids 1052 to 1082 of the latency-associated nuclear antigen (LANA) interact with RBP-Jκ and are responsible for LANA-mediated RTA repression.

Authors:  Yi Jin; Zhiheng He; Deguang Liang; Quanzhi Zhang; Hongxing Zhang; Qiang Deng; Erle S Robertson; Ke Lan
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

6.  The primary sequence of rhesus monkey rhadinovirus isolate 26-95: sequence similarities to Kaposi's sarcoma-associated herpesvirus and rhesus monkey rhadinovirus isolate 17577.

Authors:  L Alexander; L Denekamp; A Knapp; M R Auerbach; B Damania; R C Desrosiers
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

7.  Kaposi's sarcoma-associated herpesvirus expresses an array of viral microRNAs in latently infected cells.

Authors:  Xuezhong Cai; Shihua Lu; Zhihong Zhang; Carlos M Gonzalez; Blossom Damania; Bryan R Cullen
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-30       Impact factor: 11.205

8.  Primary effusion lymphoma with skin involvement.

Authors:  S Inoue; T Miyamoto; T Yoshino; I Yamadori; Y Hagari; O Yamamoto
Journal:  J Clin Pathol       Date:  2006-11       Impact factor: 3.411

9.  The phosphatase Shp2 is required for signaling by the Kaposi's sarcoma-associated herpesvirus viral GPCR in primary endothelial cells.

Authors:  Thomas Bakken; Meilan He; Mark L Cannon
Journal:  Virology       Date:  2009-12-09       Impact factor: 3.616

10.  Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression.

Authors:  R Sun; S F Lin; K Staskus; L Gradoville; E Grogan; A Haase; G Miller
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.